United States· US:62559-173_eab327c3-3ce0-4118-b1eb-76a3f247625f
Nilutamide
A nilutamide product containing nilutamide, registered in United States by ANI Pharmaceuticals, Inc.. The same ATC class is registered in 4 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Nilutamide is registered in 4 of 19 countries.
Countries holding a registration under ATC L02BB02 (nilutamide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Nilutamide · ATC L02BB02
4 / 19 countries
- Finlandprice
- Franceprice
- Netherlands
- United Statesprice
Price per daily dose
What a daily dose of nilutamide costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nilutamide · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- FR France$9.43
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NILUTAMIDE
- Manufacturer
- ANI Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- L02BB02
- ATC class
- Nilutamide
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1162559-173-31
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
291 interactions on record for nilutamide.
Graded by severity as the source publishes them — 77 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nilutamide · interactions on record
291 records
- 77 severe
- 211 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nilutamide in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAnandronsanofi-Aventis Oy
- FranceANANDRON 150 mg, compriméCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
- NetherlandsAnandron 150 mg, tablettenCHEPLAPHARM Arzneimittel GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- France · Anandron
- Netherlands · Anandron
- Portugal · Anandron
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f576ac74-c43a-45cf-bcec-c820d3c02611 GET /v1/drugs/f576ac74-c43a-45cf-bcec-c820d3c02611?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "150",
"substance": "NILUTAMIDE",
"productndc": "62559-173",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA207631",
"marketing_category": "ANDA"
}See everything about nilutamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.